Concert Pharmaceuticals, Inc.
CNCE
CNCE was delisted on the 3rd of March, 2023.
54 hedge funds and large institutions have $103M invested in Concert Pharmaceuticals, Inc. in 2014 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 14 increasing their positions, 13 reducing their positions, and 13 closing their positions.
31% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 13
25% more capital invested
Capital invested by funds: $82.6M → $103M (+$20.9M)
6% more funds holding
Funds holding: 51 → 54 (+3)
8% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 13
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SAM
Senzar Asset Management
New York
|
+$7.81M |
| 2 |
ISL
Ingalls & Snyder LLC
New York
|
+$4.53M |
| 3 |
QF
QVT Financial
New York
|
+$3.36M |
| 4 |
Millennium Management
New York
|
+$3.13M |
| 5 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$2.76M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EI
EAM Investors
Solana Beach,
California
|
-$3.82M |
| 2 |
GTC
Ghost Tree Capital
New York
|
-$3.54M |
| 3 |
RFC
Russell Frank Company
Seattle,
Washington
|
-$1.44M |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
-$1.29M |
| 5 |
TI
Turner Investments
Berwyn,
Pennsylvania
|
-$1.23M |
CNCE Hedge Fund Activity: Q4 2014 in Review
54 of the 3,751 institutional investors tracked by Wall St. Rank reported a position in Concert Pharmaceuticals, Inc. (CNCE) for Q4 2014, worth a combined $103M — up 25% from $82.6M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new CNCE positions and 13 closed out — a net gain of 4 holders — while 14 added to existing stakes and 13 trimmed.
The largest buyer was Senzar Asset Management, adding an estimated $7.81M. The largest seller was EAM Investors, exiting entirely with an estimated $3.82M sold.
- 54 institutional investors held Concert Pharmaceuticals, Inc. (CNCE) as of Q4 2014, up from 51 in Q3 2014.
- Funds reported $103M of Concert Pharmaceuticals, Inc. stock for Q4 2014, up 25% quarter-over-quarter.
- 17 funds opened new Concert Pharmaceuticals, Inc. positions in Q4 2014 and 13 closed out, a net change of +4 holders.
- The largest Concert Pharmaceuticals, Inc. buyer in Q4 2014 was Senzar Asset Management, an estimated $7.81M added.
- The largest Concert Pharmaceuticals, Inc. seller in Q4 2014 was EAM Investors, an estimated $3.82M sold.
Based on aggregated 13F filings for Q4 2014.